Cellicon^® Filter Assembly with Durapore^® Membrane

This page describes the design attributes of the Cellicon^® filter assembly for cell retention and how they simplify scale-up of intensified upstream processes.

This page describes the financial and operational advantages offered by the Cellicon® Cell Retention Device in an N-1 perfusion process at the 2,000 L scale in comparison to a cell retention device from another supplier.

How the Cellicon^® filter and controller enables seamless adoption of a perfused N-1 seed train step into the cell expansion process.

This page summarizes several performance attributes and scalability data for Mobius^® iFlex Bioreactors, single-use, stirred tank systems designed to support traditional and intensified fed-batch and perfusion cell culture applications.

Enhance perfused seed train efficiency with our cell retention solution. Real-time monitoring and control.

Biopharmaceutical developers need efficient, productive upstream processes that deliver high quality monoclonal antibodies (mAbs) and other types of recombinant proteins. Process intensification can future-proof their manufacturing strategies, reduce costs, and increase facility flexibility.

Biopharmaceutical developers need efficient, productive upstream processes that deliver high quality monoclonal antibodies (mAbs) and other types of recombinant proteins. Process intensification can future-proof their manufacturing strategies, reduce costs, and increase facility flexibility.

Before adoption of single-use technologies in biomanufacturing, manufacturers must assess the risk to the drug product from potential leachables. This article highlights a general approach based on the United States Pharmacopeia (USP).